E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor

Molecular Cancer Therapeutics

Volumn 10, Issue 7, 2011, Pages 1218-1228

  Ogino, Hirokazu ^a   Hanibuchi, Masaki ^a   Kakiuchi, Soji ^a   Van Trung, The ^a   Goto, Hisatsugu ^a   Ikuta, Kenji ^a   Yamada, Tadaaki ^a,b   Uehara, Hisanori ^a   Tsuruoka, Akihiko ^c   Uenaka, Toshimitsu ^c   Wang, Wei ^b   Li, Qi ^b   Takeuchi, Shinji ^b   Yano, Seiji ^b   Nishioka, Yasuhiko ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LENVATINIB; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CELL; CELL PROLIFERATION; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY METASTASIS; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MICROMETASTASIS; MOUSE; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; SCID MOUSE; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; MUTATION; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL ANALYSIS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79960140034     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0707     Document Type: Article

References (40)

1. Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, et al. American Society of Clinical Oncology. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2008;26:313-25.
2. Johnson DH, Blot WJ, Carbone DP, Gonzalez A, Hallahan D, Massion PP, et al. Cancer of the lung: non-small cell lung cancer and small cell lung cancer. In: Abeloff's clinical oncology. 4th ed. Philadelphia: Churchill Livingstone Elsevier; 2008. p. 1307-66.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
4. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with nonsmall- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
6. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74. (Pubitemid 43093963)
7. Lohela M, Bry M, Tammela T, Alitelo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154-65.
8. Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res 1998;58:2652-60. (Pubitemid 28275440)
9. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000;157:1893-903.
10. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 1997;16:3898-911. (Pubitemid 27281006)
11. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8. (Pubitemid 32148486)
12. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Pacliaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
13. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
14. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
15. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 2008;122:664-71. (Pubitemid 350308963)
16. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14:5459-65.
17. Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, et al. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin Cancer Res 2009;15:7229-37.
18. Kiura K, Watarai S, Shibayama T, Ohnoshi T, Kimura I, Yasuda T. Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines. Anticancer Drug Des 1993;8:417-28. (Pubitemid 24030363)
19. Yano S, Wang W, Li Q, Sakurama H, Nakamura T, Ogino H, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with EGF receptor mutations. Cancer Res 2008;68:9479-87.
20. Yano S, Nishioka Y, Izumi K, Tsuruo T, Tanaka T, Miyasaka M, et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996;67:211-7. (Pubitemid 26274152)
21. Green LM, Reade JL, Ware CF. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 1984;70:257-68. (Pubitemid 14111307)
22. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2000;12:209-17.
23. Miki T, Yano S, Hanibuchi M, Kanematsu T, Maguruma H, Sone S. Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice. Int J Cancer 2004;108:511-5. (Pubitemid 38036650)
24. Muguruma H, Yano S, Kakiuchi S, Uehara H, Kawatani M, Osada H, et al. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an anti-osteoclastic activity. Clin Cancer Res 2005;11:8822-8. (Pubitemid 43005934)
25. Matsumori Y, Yano S, Goto H, Nakataki E, Wedge SR, Ryan AJ, et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 2006;16:15-26. (Pubitemid 44195046)
26. Sauter B, Foedinger D, Sterniczky B, Wolff K, Rappersberger K. Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem 1998;46:165-76. (Pubitemid 28087847)
27. Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, et al. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Int J Cancer 2007;121:2181-91. (Pubitemid 47585596)
28. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
29. Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res 2006;12:1201-7. (Pubitemid 43342509)
30. Granata F, Frattini A, Loffredo S, Staiano RI, Petraroli A, Ribatti D, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol 2010;184:5232-41.
31. Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-50. (Pubitemid 38544126)
32. Hanibuchi M, Yano S, Nishioka Y, Yanagawa H, Kawano T, Sone S. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice. Int J Cancer 1998;78:480-5. (Pubitemid 28481167)
33. Paget S. Distribution of secondary growths in cancer of the breast. Lancet 1889;1:571.
34. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99. (Pubitemid 36577045)
35. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8. (Pubitemid 24324908)
36. Light RW. Pleural effusions related to metastatic malignancies. In: Light RW, editor. Pleural diseases. 4th ed. Philadelphia, PA: Wilkins; 2001. p. 108-34.
37. Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000;6:957-65. (Pubitemid 30159354)
38. Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, et al. Antitumor vascular strategy for controlling experimental metastatic spread of human small cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficiency mice. Clin Cancer Res 2005;11:8789-98. (Pubitemid 43005930)
39. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, et al. Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011;17:2528-37.
40. Glen H, Boss D, Morrison R, Roelvink M, Wanders J, Mazur A , et al. A phase I dose escalation and pharmacokinetic study of E7080, a small molecule tyrosine kinase inhibitor, in patients with advanced malignancies. In: 2008 ASCO Annual Meeting; 2008. Abstract 3526 handout.